Abstract
Currently, there is great interest in identifying safe and effective existing drug therapies for the prevention of coronavirus-2019 (COVID-19). Recently, there is a surge of observational studies, using big data, examining safety and effectiveness of proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) on the risk of new onset COVID-19.1–6 The nature of the disease, limitations of large databases, and use of different methodologic approaches have created unique challenges that might have contributed to contradictory studies addressing this question.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
